BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21495174)

  • 1. The musculoskeletal phenotype of the RASopathies.
    Stevenson DA; Yang FC
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):90-103. PubMed ID: 21495174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
    Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
    Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthopaedic conditions in Ras/MAPK related disorders.
    Reinker KA; Stevenson DA; Tsung A
    J Pediatr Orthop; 2011; 31(5):599-605. PubMed ID: 21654472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
    Rauen KA; Banerjee A; Bishop WR; Lauchle JO; McCormick F; McMahon M; Melese T; Munster PN; Nadaf S; Packer RJ; Sebolt-Leopold J; Viskochil DH
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):136-46. PubMed ID: 21495172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HRAS and the Costello syndrome.
    Rauen KA
    Clin Genet; 2007 Feb; 71(2):101-8. PubMed ID: 17250658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal muscle pathology in Costello and cardio-facio-cutaneous syndromes: developmental consequences of germline Ras/MAPK activation on myogenesis.
    Tidyman WE; Lee HS; Rauen KA
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):104-14. PubMed ID: 21495178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone resorption in syndromes of the Ras/MAPK pathway.
    Stevenson DA; Schwarz EL; Carey JC; Viskochil DH; Hanson H; Bauer S; Weng HY; Greene T; Reinker K; Swensen J; Chan RJ; Yang FC; Senbanjo L; Yang Z; Mao R; Pasquali M
    Clin Genet; 2011 Dec; 80(6):566-73. PubMed ID: 21204800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
    Bezniakow N; Gos M; Obersztyn E
    Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway.
    Stevenson DA; Schill L; Schoyer L; Andresen BS; Bakker A; Bayrak-Toydemir P; Burkitt-Wright E; Chatfield K; Elefteriou F; Elgersma Y; Fisher MJ; Franz D; Gelb BD; Goriely A; Gripp KW; Hardan AY; Keppler-Noreuil KM; Kerr B; Korf B; Leoni C; McCormick F; Plotkin SR; Rauen KA; Reilly K; Roberts A; Sandler A; Siegel D; Walsh K; Widemann BC
    Am J Med Genet A; 2016 Aug; 170(8):1959-66. PubMed ID: 27155140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rasopathies: developmental disorders that predispose to cancer and skin manifestations].
    Hernández-Martín A; Torrelo A
    Actas Dermosifiliogr; 2011; 102(6):402-16. PubMed ID: 21536246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.
    Zenker M
    Curr Opin Pediatr; 2011 Aug; 23(4):443-51. PubMed ID: 21750428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral muscle weakness in RASopathies.
    Stevenson DA; Allen S; Tidyman WE; Carey JC; Viskochil DH; Stevens A; Hanson H; Sheng X; Thompson BA; Okumura MJ; Reinker K; Johnson B; Rauen KA
    Muscle Nerve; 2012 Sep; 46(3):394-9. PubMed ID: 22907230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS signalling in energy metabolism and rare human diseases.
    Dard L; Bellance N; Lacombe D; Rossignol R
    Biochim Biophys Acta Bioenerg; 2018 Sep; 1859(9):845-867. PubMed ID: 29750912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and pathogenetic aspects of Noonan syndrome and related disorders.
    Zenker M
    Horm Res; 2009 Dec; 72 Suppl 2():57-63. PubMed ID: 20029240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.
    Lorenz S; Lissewski C; Simsek-Kiper PO; Alanay Y; Boduroglu K; Zenker M; Rosenberger G
    Hum Mol Genet; 2013 Apr; 22(8):1643-53. PubMed ID: 23335589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasopathies case report: concurrence of two pathogenic variations de novo in NF1 and KRAS genes in a patient.
    Baquedano Lobera I; Izquierdo Álvarez S; Oliván Del Cacho MJ
    BMC Pediatr; 2019 Apr; 19(1):92. PubMed ID: 30953504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone health in RASopathies.
    Stevenson DA; Viscogliosi G; Leoni C
    Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):459-470. PubMed ID: 36461161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of Growth Failure in Rasopathies.
    Aftab S; Dattani MT
    Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):447-458. PubMed ID: 31115196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in RASopathies.
    Aoki Y; Niihori T; Inoue S; Matsubara Y
    J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.